Alectinib for treatment of ALK-positive non-small-cell lung cancer | Future Oncology
Clinical development of targeted and immune based anti-cancer therapies | Journal of Experimental & Clinical Cancer Research | Full Text
The underlying mechanisms of lorlatinib penetration across the blood‐brain barrier and the distribution characteristics of lorlatinib in the brain - Chen - 2020 - Cancer Medicine - Wiley Online Library
Frontiers | Recent Advances in Targetable Therapeutics in Metastatic Non-Squamous NSCLC | Oncology
Drug Discovery Targeting Anaplastic Lymphoma Kinase (ALK) | Journal of Medicinal Chemistry
Therapeutic strategies and mechanisms of drug resistance in anaplastic lymphoma kinase (ALK)-rearranged lung cancer - ScienceDirect
Zykadia (Ceritinib) for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) - Clinical Trials Arena
Antitumor activity and combined inhibitory effect of ceritinib with gemcitabine in pancreatic cancer | American Journal of Physiology-Gastrointestinal and Liver Physiology
Molecular and clinical features of second-generation anaplastic lymphoma kinase inhibitors: ceritinib | Future Oncology
Cell death-based treatment of lung adenocarcinoma | Cell Death & Disease
Therapeutic management of ALK+ nonsmall cell lung cancer patients | European Respiratory Society
Pharmaceuticals | Free Full-Text | The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer | HTML
Mechanisms of resistance to crizotinib. | Download Scientific Diagram
Spotlight on ceritinib in the treatment of ALK+ NSCLC: design, develop | DDDT
Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells* - Molecular & Cellular Proteomics
Two novel strategies to overcome the resistance to ALK tyrosine kinase inhibitor drugs: Macrocyclic inhibitors and proteolysis‐targeting chimeras - Song - 2021 - MedComm - Wiley Online Library
Profile of ceritinib in the treatment of ALK+ metastatic non-small-cell lung cancer - Oncology Nurse Advisor
Agents Targeting ROS1 Gain Traction in NSCLC
Zykadia (Ceritinib) for the Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) - Clinical Trials Arena
Ceritinib - Wikipedia
Frontiers | Imprecision in the Era of Precision Medicine in Non-Small Cell Lung Cancer | Medicine
Targeting MYCN and ALK in resistant and relapsing neuroblastoma
